293 related articles for article (PubMed ID: 16755812)
1. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
2. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
3. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Biedenbach DJ; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
Jones ME; Blosser-Middleton RS; Critchley IA; Karlowsky JA; Thornsberry C; Sahm DF
Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
[TBL] [Abstract][Full Text] [Related]
5. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
7. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA;
Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Kitzis MD; Goldstein FW; Miegi M; Acar JF
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
15. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Bell JM; Turnidge JD; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
[TBL] [Abstract][Full Text] [Related]
17. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
Boswell FJ; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Oct; 50(4):495-502. PubMed ID: 12356793
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Kugler KC; Doern GV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]